SAN DIEGO, Calif., Nov. 19, 2015 /PRNewswire/ -- AnaptysBio, Inc., a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology, today announced the appointment of James A. Schoeneck to its Board of Directors.
"We are thrilled to welcome Jim to AnaptysBio's Board of Directors," said Hamza Suria, President & CEO of AnaptysBio. "Jim brings a strong track-record in building biotechnology companies and commercialization of therapeutic products. His experience is highly relevant for AnaptysBio's strategic vision to advance our anti-IL-33 antibody program to multiple clinical proof-of-concept studies and develop our anti-IL-36 receptor antibody to market launch in orphan inflammatory conditions."
Mr. Schoeneck said, "I am pleased to join AnaptysBio's Board of Directors and work closely with the company's accomplished leadership team. AnaptysBio's antibody pipeline is at the forefront of new therapeutic opportunities in inflammation and immuno-oncology. The company's validated technology platform and product development capabilities provide us a unique opportunity to rapidly advance antibody product candidates for emerging biological targets."
Mr. Schoeneck is currently President & CEO of Depomed, a publicly traded specialty pharmaceutical company. Prior to joining Depomed in 2011, Mr. Schoeneck was CEO of BrainCells Inc., ActivX BioSciences and Prometheus Laboratories Inc. Prior to Prometheus, Mr. Schoeneck led the development of Centocor's commercial capabilities, including the market launch of Remicade®, which has become one of the most successful therapeutic antibodies in history. Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi-Aventis) serving in various sales and marketing positions of increasing responsibility. Mr. Schoeneck holds a B.S. degree in Education from Jacksonville State University.
AnaptysBio is an antibody development company focused on novel programs in inflammation and immuno-oncology. The Company's proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and severe adult peanut allergy, and ANB019, an anti-IL-36 receptor antibody initially being developed for the treatment of generalized pustular psoriasis. AnaptysBio's SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery, which is designed to replicate key features of the human immune system and overcome
s limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Celgene and TESARO.